Philippines External Counterpulsation Devices Market Report Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030

Philippines External Counterpulsation Devices Market Overview

The Philippines External Counterpulsation Devices Market is valued at USD 6 million, based on a five-year historical analysis of its share within the broader Philippines medical devices market and the global external counterpulsation devices market. This growth is primarily driven by the increasing prevalence of cardiovascular diseases, rising healthcare expenditure, and advancements in medical technology, in line with the strong expansion of cardiology devices and other hospital-grade equipment in the Philippines. The demand for non-invasive treatment options, such as external counterpulsation therapy, has surged as patients seek effective alternatives to traditional surgical procedures, supported by growing clinical use of enhanced external counterpulsation (EECP) for angina, heart failure, and microcirculatory improvement. Key cities dominating this market include Metro Manila, Cebu, and Davao. Metro Manila, being the capital, has a concentration of advanced healthcare facilities and specialists, making it a hub for medical innovations and a primary locus of medical device demand in the country. Cebu and Davao are also emerging as significant players due to their growing healthcare infrastructure, expansion of private hospitals, and increasing patient populations seeking advanced cardiovascular treatments. The Universal Health Care Act (Republic Act No. 11223), enacted by the Government of the Philippines and implemented through the Department of Health and the Philippine Health Insurance Corporation, establishes a framework for equitable access to quality healthcare services nationwide and strengthens financing for essential medical services and technologies. Under this law and its implementing rules, hospitals accredited by PhilHealth are encouraged to upgrade capacity and comply with service capability standards, supporting the integration of advanced medical technologies, including external counterpulsation devices, into public and private healthcare facilities as part of improved cardiovascular care.

Philippines External Counterpulsation Devices Market Segmentation

By Product: The product segmentation includes various types of devices and accessories used in external counterpulsation therapy. The subsegments are EECP Systems, Consumables & Accessories (cuffs, hoses, ECG electrodes, others), Software & Monitoring Interfaces, and Others. Among these, EECP Systems dominate the market due to their effectiveness in treating refractory angina and heart failure and their role as the core therapeutic platform in external counterpulsation centers and hospital-based cardiology services. By Indication: The indication segmentation includes various medical conditions treated with external counterpulsation therapy. The subsegments are Refractory Angina, Heart Failure / Left Ventricular Dysfunction, Post-Myocardial Infarction Recovery, and Other Ischemic Cardiovascular Conditions. Refractory Angina is the leading indication, as it represents a significant patient population seeking non-invasive treatment options and is the primary evidence-backed use case for EECP in international clinical practice and studies.

Philippines External Counterpulsation Devices Market Market Opportunities

The Philippines External Counterpulsation Devices Market is characterized by a dynamic mix of regional and international players. Leading participants such as Vasomedical, Inc., VasoHealthcare / Vaso Corporation, Renew Group Private Limited, PSK-Health (PSK Healthcare), ScottCare Cardiovascular Solutions, Vamed Medical Instrument Co., Ltd., ACS Diagnostics, Inc., CardioMedics, Inc., Shanghai Goodmed Medical Device Co., Ltd., ANAND MEDITECH, GE HealthCare, Philips Healthcare, Medtronic plc, Abbott Laboratories, Boston Scientific Corporation contribute to innovation, geographic expansion, and service delivery in this space. Vasomedical, Inc. 1987 New York, USA –

– – – – –

VasoHealthcare / Vaso Corporation

1987 New York, USA –

– – – – –

Renew Group Private Limited

2006

Singapore–

– – – – –

PSK-Health (PSK Healthcare)

2005 Manila, Philippines –

– – – – –

ScottCare Cardiovascular Solutions

1989 Ohio, USA –

– – – – –

Company

Establishment Year

Headquarters

Group Size (Global, Regional, or Local Player) Philippines EECP Revenue (USD, Latest Year)

3-Year CAGR in EECP Revenues (Philippines)

Installed Base in Philippines (Number of EECP Systems)

Annual EECP Procedures Performed (Estimated)

Average Selling Price Positioning (Premium / Mid / Value)

Philippines External Counterpulsation Devices Market Industry Analysis

Growth Drivers

Increasing Prevalence of Cardiovascular Diseases: The Philippines faces a significant health challenge, with cardiovascular diseases accounting for approximately 30% of total deaths, as reported by the Department of Health. This alarming statistic highlights the urgent need for effective treatment options. The rising incidence of hypertension and diabetes, affecting over 13 million Filipinos, further drives the demand for external counterpulsation devices, which offer non-invasive alternatives to traditional therapies. Rising Awareness About Non-Invasive Treatment Options: As healthcare education improves, more patients are seeking non-invasive treatments for cardiovascular issues. In future, around 62% of patients expressed a preference for non-invasive therapies, according to a survey by the Philippine Heart Association. This shift in patient attitudes is fostering a greater acceptance of external counterpulsation devices, which are recognized for their safety and effectiveness, thus propelling market growth in the region. Technological Advancements in Medical Devices: The medical device sector in the Philippines is experiencing rapid technological advancements, with investments reaching approximately $1.6 billion in future. Innovations in external counterpulsation technology, such as improved device portability and user-friendly interfaces, are enhancing treatment efficacy. These advancements are crucial in attracting healthcare providers and patients alike, thereby expanding the market for these devices significantly in the coming years.

Market Challenges

High Cost of External Counterpulsation Devices: The initial investment for external counterpulsation devices can exceed PHP 1.2 million, which poses a significant barrier for many healthcare facilities in the Philippines. This high cost limits accessibility, particularly in rural areas where healthcare budgets are constrained. As a result, many patients may not receive timely treatment, hindering market growth and adoption of these devices across the country. Limited Reimbursement Policies: The lack of comprehensive reimbursement policies for external counterpulsation therapy remains a critical challenge. In future, only 32% of health insurance plans in the Philippines cover these devices, according to the Insurance Commission. This limited coverage discourages healthcare providers from investing in such technologies, ultimately affecting patient access to these potentially life-saving treatments and stalling market expansion.

Philippines External Counterpulsation Devices Market Future Outlook

The future of the external counterpulsation devices market in the Philippines appears promising, driven by increasing healthcare investments and a growing focus on preventive care. As the government aims to enhance healthcare infrastructure, the integration of advanced technologies will likely improve patient outcomes. Additionally, the rising geriatric population, projected to reach 13 million in future, will further fuel demand for non-invasive treatment options, creating a favorable environment for market growth and innovation.

Market Opportunities

Expansion of Healthcare Infrastructure: The Philippine government is investing approximately PHP 120 billion in healthcare infrastructure in future. This investment will enhance access to advanced medical technologies, including external counterpulsation devices, particularly in underserved areas, thereby increasing market penetration and improving patient care. Growing Geriatric Population: With the geriatric population expected to reach 13 million in future, there is a significant opportunity for external counterpulsation devices. This demographic is more susceptible to cardiovascular diseases, creating a robust demand for effective, non-invasive treatment options that cater specifically to their healthcare needs.

Please Note: The report will take approximately 4–6 weeks to prepare and deliver.

Update cycle typically involves:

Dataset refresh & triangulation from credible public sources + paid databases where applicable.
Competitive mapping (platform coverage, business model, revenue/traffic proxies where available, key vertical splits)
Validation pass to ensure numbers are directionally consistent (and avoid “stale” assumptions)
Finalizing the PDF + Excel with clear assumptions and definitions. Show more